Month: August 2025

Bell & Ross has long cemented its identity in the world of professional aviation, crafting instrument watches that are as much a part of a pilot’s toolkit as the gauges on the dashboard. This commitment takes a new flight with the BR-03 Chrono Rafale Solo Display, a limited-edition timepiece celebrating the brand’s new partnership with the Rafale Solo Display, the official flight demonstration program of the French Air and Space Force.

Announced at the Paris Air Show, the collaboration highlights a shared philosophy of precision, performance, and innovation. The Rafale Solo Display, an elite team showcasing the exceptional capabilities of the Dassault Rafale fighter jet, performs nine-minute aerial ballets of breathtaking maneuvers. The absolute precision required for these displays—which captivate audiences at international airshows—is mirrored in the exacting standards of Bell & Ross’s watchmaking.

The new BR-03 Chrono is a fitting tribute to this high-octane partnership. The watch is presented in a 42mm micro-blasted black ceramic case, a signature of the brand that echoes the anti-reflective finish of aircraft instruments. The matte black dial provides a high-contrast canvas for the white numerals and indices, ensuring optimal legibility. A subtle, yet powerful, tribute to the Rafale team is found in the bursts of orange and yellow on the chronograph sub-dials and hands, mirroring the colors of the Rafale Solo Display’s logo. The watch’s chronograph pushers are also uniquely engraved with “START” and “RESET” and filled with colored lacquer.

The BR-03 Chrono Rafale Solo Display is powered by the automatic BR-CAL.301 movement. The watch comes with two straps: a black open-worked rubber strap and an ultra-resilient black synthetic fabric strap emblazoned with the Rafale Solo Display logo. This combination of ruggedness and style reinforces the timepiece’s dual role as a high-performance instrument and a compelling piece of design. Limited to 500 pieces, the new watch continues Bell & Ross’s tradition of creating handsome tool watches for collectors and military personnel alike. The BR-03 Chrono Rafale Solo Display is available for $6,000.

Even after seven years of work and securing a multibillion-dollar valuation $4 billion Skims valuation, Kim Kardashian is still happy to slip into her shapewear brand’s garments for the ‘gram. The reality star and entrepreneur posed in Skims’ new see-through Milky Sheer String Bikini, which comes emblazoned with the words “curious,” “feelings,” and “temptation” along the backside.

As Page Six notes, the cursive font in particular was interpreted as nostalgic by multiple commenters. One hoped for an Ed Hardy collaboration, apparently drawing a connection with the 2000s-era fashion label’s Ed Hardy logo and the “Curious” script, while another felt the style exuded “90s vibes.”

Kardashian’s latest pics come shortly after Skims Men’s unveiled a massive campaign featuring Post Malone in a new collection of underwear, tees, and camouflage heavyweight fleece loungewear. While shooting the campaign in Oakley, Utah— the same state where the 18-time Grammy nominee resides—he proclaimed a very real love of camo in a GQ interview.

“I love Realtree camouflage. I love camouflage in general. Some people are passionate about a lot of stuff, like some people build spaceships and stuff, and I just like camouflage and anything that is in that vein. Speaking of, I just did the underwear shot, and that underwear is gangster. It is so soft on my stuff. My special stuff. And they made me a special one-off robe that I’m obsessed with.”

View this post on Instagram

A post shared by @postmalone

The Skims Milky Sheer bikini and Skims Men’s Realtree camo collection are both available to purchase now.

Members of our editorial staff were not involved in the creation of this content.

When people think about longevity, the focus often turns to cardiovascular health, testosterone, or fitness. Yet cognitive decline is one of the most devastating and preventable threats to long-term quality of life. Neurogen Biomarking, a Chicago-based startup founded in 2024 by neurologist Dr. Rany Aburashed, is addressing this blind spot head-on. 

Early Detection, Delivered To Your Door

At the core of Neurogen’s offering is a simple at-home test that measures phosphorylated tau 217 (pTau217), a highly sensitive biomarker for early Alzheimer’s. The process is designed for ease: a small blood sample, followed by a cognitive assessment, and a virtual consultation with a board-certified neurologist. 

This full ecosystem can potentially identify early indicators of Alzheimer’s, sometimes 10 to 20 years before symptoms appear, and provide clinical guidance tailored to a person’s overall health. 

From Data To Direction 

Where most diagnostic platforms deliver numbers, Neurogen delivers guidance. Every result is reviewed by a neurologist who accounts for the patient’s broader health picture, such as cardiovascular risk or previous injuries. This helps ensure that patients receive clarity, not confusion, and it’s a major point of differentiation in a crowded diagnostics market. 

The Problem That Inspired A Company 

Dr. Aburashed launched Neurogen after repeatedly observing patients being diagnosed too late to benefit from interventions or proactive planning. Even with groundbreaking treatments, he realized only 8 percent of individuals would qualify to receive those treatments under current diagnostic practices. In other words, if a cure existed tomorrow, the vast majority would miss their opportunity entirely. Recognizing this critical gap, he set out to transform how Alzheimer’s detection is approached responsibly, thoughtfully, and proactively. 

Built With Scientific And Strategic Depth

Neurogen’s strength lies in its integration of advanced science and operational precision. The leadership team includes chief scientific officer Dr. Elisabeth Thijssen, a global expert in Alzheimer’s biomarkers, and chief strategy officer Dr. Ken Bahk, who brings deep experience scaling healthcare ventures. The company’s distinguished advisory board includes renowned experts from Harvard, Wake Forest, and Amsterdam University Medical Centers, underscoring Neurogen’s commitment to scientific excellence and strategic foresight. 

A New Standard For People Over 40 

For people entering midlife, particularly those with a family history of Alzheimer’s, Neurogen may offer a way to proactively explore brain health without the need for hospital visits or waiting for symptoms to appear. This approach can shift cognitive care from reactive to preventative. Recent research from the Alzheimer’s Association further validates this approach: their 2025 Facts & Figures report revealed that more than 80 percent of Americans would prefer to know their Alzheimer’s risk status early, underscoring the widespread demand for proactive cognitive care. 

More than 1,000 individuals joined the Neurogen waitlist before launch, and over 500 have completed beta testing with 98 percent satisfaction. The demand signals a larger trend: Men want earlier insight and greater control. 

The Vision: Make Brain Health Routine 

Neurogen’s goal is to make brain screenings as standard as cholesterol checks. By combining scientific rigor with digital accessibility, the company is laying the groundwork for a future in which cognitive health becomes part of everyday preventive care. Visit www.neurogenbiomarking.com to learn more

This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.